marketwatch
: Gilead Sciences says FDA has approved Veklury in COVID patient with severe renal impairment
MarketWatch • 2 YEARS AGO
: Tidewater started at strong buy with $85 stock price target at Raymond James
MarketWatch • 2 YEARS AGO
: JPMorgan Chase lifts 2023 view for net interest income and net interest income excluding markets to about $87 bln, up from earlier view of about $81 bln
MarketWatch • 2 YEARS AGO
